Through patient education, dose adjustments, and supportive care, these side effects can be mitigated, allowing patients to reap the full benefits of this medication
Genetic testing, inflammatory profiles, or tissue imaging predicting responsiveness allowing personalized protocol selection
Results demonstrated substantial reductions in liver fat content at 24 weeks across all active doses, with the 8 mg and 12 mg doses producing mean relative liver fat reductions of 81.4% and 82.4% respectively, compared to a +0.3% change with placebo
The patient was compliant and expressed understanding with all treatment received
GLP-1 Receptor Agonists in Broader Mental Health Applications Beyond addiction and binge eating disorder, researchers are exploring the potential use of GLP-1 receptor agonists in treating other mental health conditions, such as depression and anxiety